With childhood immunization rates sliding and outbreaks accelerating, pharmacist-led counseling and vaccine administration can boost vaccination rates.
|Podcasts|July 11, 2022
Pharmacy Focus: Move the Needle Monday- Pediatric COVID-19 Immunization Updates
There is new guidance needed for pediatric immunizations, and pharmacists should be prepared for what's to come.
Advertisement
In this month's episode, Ed Cohen and John Beckner from NCPA are joined by Mitchel Rothholz, RPh, MBA, Chief of Governance & State Affiliates- American Pharmacists Association, and Executive Director, APhA Foundation, about pediatric COVID-19 doses and preparation for flu season.
Advertisement
Related to this article
A Danish registry study found that COVID-19 infection was linked to a lower, not higher, risk of subsequent type 1 diabetes (T1D) in unvaccinated individuals younger than 30 years.
A high-dose vaccine cut hospitalizations for flu, pneumonia, and cardiorespiratory disease in older adults with asthma, COPD, and other chronic lung conditions.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
Pharmacists play a key role in guiding age- and risk-based vaccination decisions to protect against invasive and noninvasive disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
FDA Reduces Monitoring Time for First Two Tarlatamab Doses
4
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
5